This dashboard, produced under the BioPIC project, reflects all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new late stage biomedical HIV PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring. To update or add any activities missing from the dashboard, or if you have questions on using the dashboard, please contact Catherine Verde Hashim to ensure they are included in the next update.
As a collaborative platform, BioPIC supports introduction, planning, and information sharing for the successful introduction of HIV prevention products. One of BioPIC’s key roles is to serve as a clearinghouse to monitor ongoing and planned activities related to HIV prevention and product introduction with a particular focus on injectable cabotegravir for PrEP. The goal is to facilitate a shared understanding of the various partners, funders, location, scope, and focus of various implementation research and projects.
Normative Guidance/Policies, Service Delivery, Vertical Transmission
Elimination of vertical transmission of HIV will require expanded access to HIV prevention strategies, such as PrEP, for pregnant and breastfeeding people. Guidance from the World Health Organization (WHO) supports provision of HIV pre-exposure prophylaxis (PrEP) to pregnant and breastfeeding people (PBFP) who are at continuing substantial risk of HIV infection. Evidence has shown that…
Injectable PrEP Factsheet for MSM Advocates and Community Members in the Asia-Pacific Region
Value Chain Situation Analysis for CAB PrEP – Interview Guide
The interview question bank is designed to help identify questions to ask stakeholders in interviews to inform a situation analysis for CAB PrEP.
Value Chain Situation Analysis for CAB PrEP – Overview Guide
This tool can be used by policymakers or others supporting policy development for CAB PrEP (e.g., nongovernmental organizations, donors) to conduct an analysis to assess the existing situation for the introduction of the new product. The guide facilitates a structured process in three steps to support initial planning for CAB PrEP introduction: data collection, stakeholder…
Dual Prevention Pill: Market Preparation and Introduction Strategy
This strategy, updated in August 2023, is intended for donors, governments, implementing partners and civil society to inform priorities and planning for DPP rollout. The strategy describes activities required to build a cohesive body of evidence and recommends an approach to DPP introduction to focus efforts. Where possible, activities will be embedded into existing programs…
Feasibility of Long Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C.
This poster presentation, delivered at IAS 2023 by the Whitman-Walker Institute, describes the integration of long acting injectable cabotegravir for PrEP, administered by community health workers, or non medically licensed staff, in a primary health clinic in Washington, D.C., USA.
Shaping and Coordinating the Implementation Science Agenda for Injectable Cabotegravir for PrEP: The role of the Biomedical Prevention Implementation Collaborative (BioPIC)
This article from JIAS describes the coordinated approach taken by the Biomedical Prevention Implementation Collaborative (BioPIC) to ensure questions regarding delivery of cabotegravir (CAB) for PrEP are addressed so that CAB can be introduced in low- and middle-income countries in timely, acceptable and effective ways.
Counterfactual Estimation of Efficacy against Placebo for Novel PrEP Agents Using External Trial Data: Example of injectable cabotegravir and oral PrEP in women
This article from JIAS uses estimated prevention efficacy against a counterfactual placebo to provide information on the use of cabotegravir for PrEP and oral PrEP compared to no intervention.
Adolescent Girls and Young Women’s Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: A multi-country qualitative analysis
This article from AIDS and Behavior explores adolescent girls and young women’s experiences in disclosing use of oral PrEP and the dapivirine vaginal ring in South Africa, Uganda, and Zimbabwe.
Baseline Preferences for Oral Pre-Exposure Prophylaxis (PrEP) or Dapivirine Intravaginal Ring for HIV Prevention Among Adolescent Girls and Young Women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 Study)
This journal article from PLOS ONE explored baseline preferences for oral PrEP or the dapivirine ring for AGYW (adolescent girls and young women) in South Africa, Uganda, and Zimbabwe.